Stock VLAP VALNEVA SE PREF.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Valneva SE Pref. Euronext Paris

Equities

VLAP

FR0011472943

Real-time Euronext Paris
Other stock markets
 		5-day change 1st Jan Change
- EUR -.--% Intraday chart for Valneva SE Pref. -7.89% -28.57%
08:24am Valneva: new positive data in CHIKV CF
05-07 Valneva SE Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the past twelve months, EPS forecast has been revised upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • One of the major weak points of the company is its financial situation.
  • The company appears highly valued given the size of its balance sheet.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
VALNEVA SE PREF. Stock Valneva SE Pref.
-28.57% 503M -
MODERNA, INC. Stock Moderna, Inc.
+23.93% 44.96B
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.40% 42.65B
B
LONZA GROUP AG Stock Lonza Group AG
+46.00% 41.85B
A
CELLTRION, INC. Stock Celltrion, Inc.
-5.31% 29.04B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.80% 26.08B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.14% 19.03B
B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+6.86% 12.75B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.27% 12.06B
C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.40% 11.75B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. VLA Stock
  4. VLAP Stock
  5. Ratings Valneva SE Pref.